Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia

Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL). Thus, there is ongoing demand for novel agents. Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stage. CDK9 mediating RNA transcriptional elongation i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Göthert, Joachim R., Imsak, Roze, Möllmann, Michael, Kesper, Stefanie, Göbel, Maria, Dührsen, Ulrich, Scholz, Arne, Lücking, Ulrich, Baumann, Matthias, Unger, Anke, Schultz-Fademrecht, Carsten, Klebl, Bert, Eickhoff, Jan, Choidas, Axel, Dürig, Jan
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995184/
https://ncbi.nlm.nih.gov/pubmed/29899864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25293
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires